The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2016
Filed:
May. 27, 2010
Neil Almstead, Princeton, NJ (US);
Tamil Arasu, Edison, NJ (US);
Soongyu Choi, Skillman, NJ (US);
Liangxian Cao, Parlin, NJ (US);
Jeffrey Allen Campbell, Hilton Head Island, SC (US);
Donald Corson, Erie, CO (US);
Thomas W. Davis, South Orange, NJ (US);
Jason D. Graci, Scranton, PA (US);
Zhengxian Gu, Princeton, NJ (US);
Peter Seongwoo Hwang, Edison, NJ (US);
William Lennox, Bedminster, NJ (US);
Harry H. Miao, Wellsley, MA (US);
Langdon Miller, Seattle, WA (US);
Young-choon Moon, Belle Mead, NJ (US);
Hongyan Qi, Plainsboro, NJ (US);
Christopher Trotta, Somerset, NJ (US);
Marla L. Weetall, Morristown, NJ (US);
Neil Almstead, Princeton, NJ (US);
Tamil Arasu, Edison, NJ (US);
Soongyu Choi, Skillman, NJ (US);
Liangxian Cao, Parlin, NJ (US);
Jeffrey Allen Campbell, Hilton Head Island, SC (US);
Donald Corson, Erie, CO (US);
Thomas W. Davis, South Orange, NJ (US);
Jason D. Graci, Scranton, PA (US);
Zhengxian Gu, Princeton, NJ (US);
Peter Seongwoo Hwang, Edison, NJ (US);
William Lennox, Bedminster, NJ (US);
Harry H. Miao, Wellsley, MA (US);
Langdon Miller, Seattle, WA (US);
Young-Choon Moon, Belle Mead, NJ (US);
Hongyan Qi, Plainsboro, NJ (US);
Christopher Trotta, Somerset, NJ (US);
Marla L. Weetall, Morristown, NJ (US);
PTC Therapeutics, Inc., South Plainfield, NJ (US);
Abstract
Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.